Published in Nat Rev Cancer on August 17, 2012
Tumour suppressors: Different roads to inactivation. Nat Rev Cancer (2009) 1.13
Epithelial-mesenchymal transition: Untangling EMT's functions. Nat Rev Cancer (2015) 0.86
Metastasis: dynamic interactions. Nat Rev Cancer (2012) 0.86
Prostate cancer: BETting on epigenetic therapy. Nat Rev Cancer (2014) 0.83
Non-coding RNAs: The cancer X factor. Nat Rev Cancer (2013) 0.82
Hypoxia: HIF switch. Nat Rev Cancer (2011) 0.81
Metastasis: Recharging with COCO. Nat Rev Cancer (2012) 0.81
Tumour microenvironment: Means of resistance. Nat Rev Cancer (2013) 0.80
Tumorigenesis: Pushing pancreatic cancer to take off. Nat Rev Cancer (2012) 0.80
Pancreatic cancer: Fibroblast co-conspirators. Nat Rev Cancer (2011) 0.79
Oncogenes: All eyes on YAP1. Nat Rev Cancer (2014) 0.79
Epigenetics: Place your BETs. Nat Rev Cancer (2015) 0.78
Tumour immunology: dendritic cell switch. Nat Rev Cancer (2012) 0.78
Hypoxia: New connections. Nat Rev Cancer (2012) 0.78
Tumour suppressors: PTEN surprise. Nat Rev Cancer (2013) 0.78
Signalling: Seeing the big picture. Nat Rev Cancer (2013) 0.78
Cancer stem cells. VEGF promotes stemness. Nat Rev Cancer (2011) 0.78
MicroRNAs: Editing changes the meaning. Nat Rev Cancer (2012) 0.78
Metastasis: Signalling in transit. Nat Rev Cancer (2011) 0.78
Genetics: p53 variant increases cancer risk. Nat Rev Cancer (2016) 0.77
Tumour microenvironment: Teaching old macrophages new tricks. Nat Rev Cancer (2013) 0.77
Microenvironment: Endothelial cells create a niche. Nat Rev Cancer (2014) 0.77
Chemotherapy: Preventing competitive release. Nat Rev Cancer (2016) 0.77
Metabolism: flexible flux. Nat Rev Cancer (2011) 0.77
Cytokine cues. Nat Rev Cancer (2011) 0.77
Prostate cancer: Connecting androgen receptor and immunity. Nat Rev Cancer (2016) 0.77
Therapeutics: siRNAs jump the hurdle. Nat Rev Cancer (2012) 0.77
Hepatocellular carcinoma: gender differences. Nat Rev Cancer (2014) 0.77
Therapeutic resistance: two steps ahead. Nat Rev Cancer (2013) 0.77
Tumour immunology: An exhausting metabolic competition. Nat Rev Cancer (2015) 0.76
Layers of regulation. Nat Rev Cancer (2011) 0.76
Colorectal cancer: A powerful model. Nat Rev Cancer (2012) 0.76
Oncogenes: One of these things is not like the others. Nat Rev Cancer (2015) 0.76
Microenvironment: Making connections. Nat Rev Cancer (2013) 0.76
Colorectal cancer: APC restores order. Nat Rev Cancer (2015) 0.76
Tumour heterogeneity: A cooperative tumour cell community. Nat Rev Cancer (2014) 0.76
Tumour microenvironment: Destroying leukaemia stem cell habitats. Nat Rev Cancer (2013) 0.76
Therapeutics: delving deeper into resistance. Nat Rev Cancer (2014) 0.76
Colorectal cancer: A circuitous way to target p53. Nat Rev Cancer (2015) 0.76
Tumour suppressors: Hippo promotes microRNA processing. Nat Rev Cancer (2014) 0.76
Ovarian cancer: Driving force. Nat Rev Cancer (2011) 0.76
Immunotherapy: Two antigens are better than one. Nat Rev Cancer (2016) 0.76
Immunotherapy: Combinations that work. Nat Rev Cancer (2012) 0.76
Metastasis: multitasking hyaluronic acid. Nat Rev Cancer (2012) 0.76
Oncogenes: direct hit on mutant RAS. Nat Rev Cancer (2013) 0.76
Bladder cancer: No cohesion for cohesin's role. Nat Rev Cancer (2013) 0.75
Medulloblastoma: Fuelling the debate. Nat Rev Cancer (2013) 0.75
Cancer stem cells: Easily moulded. Nat Rev Cancer (2013) 0.75
Leukaemia: exploring origins and evolution. Nat Rev Cancer (2015) 0.75
Ovarian cancer: At the starting line. Nat Rev Cancer (2013) 0.75
MicroRNAs: Lines of communication. Nat Rev Cancer (2012) 0.75
Tumorigenesis: Order matters. Nat Rev Cancer (2015) 0.75
Leukaemia: fine-tuning metabolism. Nat Rev Cancer (2014) 0.75
Angiogenesis: The new normal. Nat Rev Cancer (2012) 0.75
Metabolism: Metabolic block. Nat Rev Cancer (2013) 0.75
Lymphoma: Epigenetic therapy gains momentum. Nat Rev Cancer (2012) 0.75
Therapeutic resistance: ALL-important mutations. Nat Rev Cancer (2013) 0.75
Microenvironment: source influences function. Nat Rev Cancer (2014) 0.75
Pancreatic cancer: A matter of timing. Nat Rev Cancer (2015) 0.75
Metastasis: opposing forces in invasion. Nat Rev Cancer (2011) 0.75
Metabolism: Taking it all in. Nat Rev Cancer (2013) 0.75
Signalling: location, location, location. Nat Rev Cancer (2011) 0.75
Domino effect. Nat Rev Cancer (2012) 0.75
Immunotherapy: Primed for a response. Nat Rev Cancer (2015) 0.75
Cell migration: changing shape. Nat Rev Cancer (2015) 0.75
Tumour suppressors: Notch blocks bladder tumorigenesis. Nat Rev Cancer (2014) 0.75
Metastasis: Working in groups. Nat Rev Cancer (2014) 0.75
Epigenetics: Chromatin reorganization on a 'mega' scale. Nat Rev Cancer (2015) 0.75
Breast cancer: Untangling the role of progesterone receptors. Nat Rev Cancer (2015) 0.75
Lymphoma. Suppressive EPH-ect. Nat Rev Cancer (2011) 0.75
Ovarian cancer: A better mimic. Nat Rev Cancer (2014) 0.75
Field effect. Nat Rev Cancer (2012) 0.75
RNA splicing: Layered regulation. Nat Rev Cancer (2012) 0.75
Scheduled delivery. Nat Rev Cancer (2012) 0.75
Tumour microenvironment: Tumours have a lot of nerve. Nat Rev Cancer (2013) 0.75
Navigating uncharted territory. Nat Rev Cancer (2012) 0.75
Cancer metabolism: feed it forward. Nat Rev Cancer (2011) 0.75
Cancer genomics: coming in waves. Nat Rev Cancer (2013) 0.75
Angiogenesis: What's the alternative? Nat Rev Cancer (2012) 0.75
Epigenetics: Methylation reboot. Nat Rev Cancer (2013) 0.75
Polarity: Merlin and ezrin get organized. Nat Rev Cancer (2013) 0.75
Metabolism: Catabolic effects. Nat Rev Cancer (2011) 0.75
Tumour metabolism: Functions of fumarate. Nat Rev Cancer (2016) 0.75
Ovarian cancer: Model building. Nat Rev Cancer (2011) 0.75
Glioma: Tumour cells in reverse. Nat Rev Cancer (2012) 0.75
Genomic instability: Building bridges. Nat Rev Cancer (2015) 0.75
Signalling: Double trouble. Nat Rev Cancer (2012) 0.75
Microenvironment: an accommodating host. Nat Rev Cancer (2013) 0.75
Senescence: Improved detection. Nat Rev Cancer (2013) 0.75
Glioblastoma: Transforming fusions induce aneuploidy. Nat Rev Cancer (2012) 0.75
Tumour virology. Entry requirements. Nat Rev Cancer (2012) 0.75
Tumour immunology: Promoting tolerance. Nat Rev Immunol (2010) 0.75
Non-coding RNA: Stressed to bits. Nat Rev Cancer (2015) 0.75
Prostate cancer. Mutational consequences. Nat Rev Cancer (2012) 0.75
Cachexia: Putting the brakes on lipid loss. Nat Rev Cancer (2011) 0.75
Therapeutics. Another tool in the BCR-ABL kit? Nat Rev Cancer (2011) 0.75
Cancer genomics: Finding a rare variant. Nat Rev Cancer (2011) 0.75
Signalling: uncovering new functions of PI3K mutations. Nat Rev Cancer (2014) 0.75
RNA splicing: MYC maintains high-fidelity splicing. Nat Rev Cancer (2015) 0.75
Oesophageal cancer: Model refinement. Nat Rev Cancer (2015) 0.75